Daily Respiratory Research Analysis
Analyzed 186 papers and selected 3 impactful papers.
Summary
Today’s top respiratory studies span practice-changing vaccine coadministration, a highly innovative intranasal VLP-encoding adenoviral platform for multiplexed mucosal protection, and a mechanistic advance identifying CCR5+ NK cells as drivers of hypoxemia in acute lung injury. Together they illustrate immediate immunization workflow benefits, a path toward durable mucosal immunity against respiratory pathogens, and a druggable target for ARDS biology.
Research Themes
- Vaccine coadministration and immunization logistics in older adults
- Mucosal vaccine platforms enabling durable, multiplexed respiratory protection
- Innate lymphocyte trafficking (CCR5+ NK cells) as a therapeutic target in acute lung injury
Selected Articles
1. Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age.
In a phase III, open-label randomized trial (n=530), coadministration of adjuvanted RSVPreF3 with RZV in adults ≥50 met prespecified non-inferiority for RSV-A/B neutralization and anti-gE responses compared with sequential dosing. Reactogenicity (solicited systemic AEs) was modestly higher with coadministration, without related serious adverse events.
Impact: This directly informs immunization programs by enabling same-day administration of RSV and zoster vaccines in older adults, simplifying logistics and improving uptake.
Clinical Implications: Clinicians can offer coadministration of RSVPreF3 and RZV to adults ≥50, counseling about slightly higher short-term systemic reactogenicity and maintaining routine safety monitoring.
Key Findings
- Non-inferiority met: RSV-A GMT ratio 1.1 (95% CI 1.0–1.4), RSV-B 1.0 (0.8–1.2), anti-gE GMC ratio 1.2 (1.1–1.4) comparing sequential/control vs coadministration.
- Higher solicited systemic AEs after visit 1 with coadministration (73.6%; grade 3 9.3%) versus control (60.4%; grade 3 6.2%).
- No fatal or related serious adverse events; unsolicited AEs within 30 days were comparable or lower in coadministration (23.4%) vs control (30.2%).
Methodological Strengths
- Randomized, controlled phase III design with prespecified non-inferiority margins.
- Objective, laboratory-based immunogenicity endpoints and adequate sample size (n=530).
Limitations
- Open-label design may influence reactogenicity reporting.
- Short-term immunogenicity endpoints; clinical effectiveness and rare safety events require longer follow-up.
Future Directions: Evaluate clinical effectiveness (RSV, zoster outcomes), durability of responses, and safety in frailer subgroups; assess coadministration with additional vaccines in diverse healthcare settings.
BACKGROUND: Co-administration of AS01E-adjuvanted respiratory syncytial virus vaccine (adjuvanted RSVPreF3) and AS01B-adjuvanted recombinant herpes zoster subunit vaccine (RZV), although not contraindicated, has not been previously studied in clinical trials. METHODS: This phase III, open-label, randomized (1:1) trial evaluated the immunogenicity, safety, and reactogenicity of adjuvanted RSVPreF3 when co-administered with RZV in ≥50-year-olds. The 2 vaccines were either co-administered at visit 1 (day [D] 1; Co-Ad), or were given sequentially, 1 month apart (RZV dose 1 at D1, adjuvanted RSVPreF3 at D31; Control). All participants received RZV dose-2 at D61. Non-inferiority of humoral immune responses was demonstrated if 95% confidence interval (CI) upper limits for geometric mean RSV-A/B neutralizing titers (GMT) and varicella-zoster virus anti-glycoprotein E (anti-gE) antibody concentration (GMC) ratios (Control/Co-Ad) were ≤1.5. Safety and reactogenicity were secondary endpoints. RESULTS: Overall, 530 participants (Co-Ad = 265; Control = 265) were vaccinated. Neutralizing GMT ratios for RSV-A (1.1 [95% CI = 1.0-1.4]) and RSV-B (1.0 [0.8-1.2]), and anti-gE antibody GMC ratio (1.2 [1.1-1.4]) met non-inferiority criteria. Within 7 days post-vaccination, 71.7% (Co-Ad: post-RZV dose 1 and adjuvanted RSVPreF3; grade [Gr] 3 = 3.9%), 58.5% (Control: post-RZV dose 1; Gr3 = 1.9%), and 47.8% (Control: post-adjuvanted RSVPreF3; Gr3 = 1.2%) of participants reported solicited administration-site adverse events (AEs). Post-visit 1, 73.6% (Gr3 = 9.3%) of Co-Ad and 60.4% (Gr3 = 6.2%) of control participants reported solicited systemic AEs. Within 30 days post-any vaccination, 23.4% (Gr3 = 0.8%) of Co-Ad and 30.2% (Gr3 = 1.1%) of control participants reported unsolicited AEs. No fatal or related serious AEs were reported. CONCLUSIONS: Immunogenicity, reactogenicity, and safety data support the co-administration of adjuvanted RSVPreF3 and RZV. CLINICAL TRIALS REGISTRATION: NCT05966090.
2. An Ad5-vectored platform generating self-assembling VLPs elicits potent mucosal immunity against influenza A virus and SARS-CoV-2.
An intranasal Ad5 platform encoding in vivo–assembling VLPs induced durable mucosal and systemic immunity, outperforming intramuscular dosing and protecting against homologous and heterologous influenza in mice. It also generated cross-neutralizing antibodies to SARS-CoV-2 variants and, when coexpressing S and HA, produced dual neutralization and pulmonary sIgA; the approach extended to rabies models across species.
Impact: It introduces a versatile, single-dose, intranasal, multiplexed mucosal vaccine strategy with broad respiratory relevance, addressing the unmet need for robust pulmonary immunity to limit infection and transmission.
Clinical Implications: While preclinical, this platform supports advancing intranasal VLP-encoding vectors into human trials to achieve durable mucosal protection against influenza and SARS-CoV-2, and potentially multiplexed respiratory vaccines.
Key Findings
- Single-dose intranasal Ad5-HA-VLP provided long-lasting protection against homologous and heterologous influenza, outperforming intramuscular administration.
- scRNA-seq and flow cytometry showed recruitment/reprogramming of lung innate immune cells, driving robust mucosal sIgA and CTL responses.
- Ad5-S-VLP elicited cross-neutralizing antibodies against SARS-CoV-2 variants; Ad5-S-HA-VLP induced dual influenza and SARS-CoV-2 neutralization and pulmonary antigen-specific sIgA.
- Ad5-RVDG-VLP conferred broad protective immunity in mouse, dog, and cat rabies models.
Methodological Strengths
- Multimodal immune profiling (single-cell transcriptomics and flow cytometry) linking mechanism to protection.
- Demonstrated breadth across pathogens and species, including dual-antigen coexpression and single-dose efficacy.
Limitations
- Preclinical animal studies; human safety, pre-existing Ad5 immunity, shedding, and manufacturing/translational logistics remain to be addressed.
- Comparative effectiveness versus existing intranasal or systemic platforms was not clinically assessed.
Future Directions: Phase 1 trials to assess safety, mucosal/systemic immunogenicity and durability; evaluate performance in populations with pre-existing anti-Ad5 immunity; head-to-head comparisons and multiplexed pathogen coverage.
Integrating complementary vaccine modalities is essential for combating emerging pathogens. Although the recent mRNA-VLP hybrids enable spontaneous virus-like particles (VLPs) self-assembly, thereby enhancing immunogenicity, they fail to elicit robust pulmonary mucosal immunity against respiratory pathogens. Here, we developed Ad5-Envp-VLP, a chimeric adenoviral platform enabling spontaneous in vivo assembly of envelope protein-displaying VLPs using advanced technology that recruits ESCRT (endosomal sorting complex required for transport) via the EABR (ESCRT and ALIX-binding region). Compared with the intramuscular route, intranasal administration of a single-dose Ad5-HA-VLP confers long-lasting protection against both homologous and heterologous influenza A strains. Integrated single-cell RNA sequencing and flow cytometry analyses reveal that intranasal delivery of Ad5-HA-VLP recruits and functionally reprograms lung innate immune cells, promoting antigen presentation and driving robust mucosal secretory IgA (sIgA) secretion and cytotoxic T lymphocyte responses. Similarly, intranasal delivery of Ad5-S-VLP elicits potent cross-neutralizing antibody titers against SARS-CoV-2 variants. Importantly, intranasal immunization with Ad5-S-HA-VLP (coexpressing S- and HA-VLPs) generates dual influenza and SARS-CoV-2 neutralizing antibodies, alongside pulmonary antigen-specific sIgA, confirming Ad5-Envp-VLP as a promising "single-dose multiplexed mucosal vaccine" against respiratory pathogens. Further extended applications show that Ad5-RVDG-VLP also induces broad protective immunity in mouse, dog, and cat models, verifying its feasibility as an efficient rabies vaccine. Collectively, the Ad5-Envp-VLP platform represents a universal and versatile mucosal vaccine strategy, leveraging pulmonary delivery of vectors that encode in vivo-assembling VLPs to concurrently elicit robust mucosal and systemic immunity against a wide spectrum of pathogens.
3. CCR5+ NK cells drive hypoxemia in endotoxin-induced acute lung injury.
In endotoxin-induced ALI, CCR5+ NK cells expanded, expressed tissue-resident features, and mediated injury. Pharmacologic CCR5 blockade reduced NK trafficking and lung injury, with benefit even when given 2 hours post-LPS; adoptive transfer of Ccr5-null NK cells recapitulated protection.
Impact: It identifies a mechanistic and druggable axis—CCR5-dependent NK trafficking—that drives hypoxemia in ALI, supporting rationale to test CCR5 antagonists in ARDS endotypes.
Clinical Implications: CCR5 antagonism (e.g., repurposed agents) warrants translational investigation in human ARDS subsets enriched for CCR5+ NK signatures, with biomarker-guided patient selection.
Key Findings
- CCR5 ligands and CCR5+ NK cells were increased in endotoxin-induced ALI; these NK cells displayed tissue-resident markers.
- CCR5 inhibition reduced NK trafficking in BAL and ameliorated lung injury across multiple domains; T cells were less affected.
- Adoptive transfer of Ccr5-null NK cells reduced trafficking and injury versus wildtype; CCR5 inhibition effective even when given 2 hours post-LPS.
Methodological Strengths
- Convergent genetic (Ccr5 knockout/adoptive transfer) and pharmacologic inhibition approaches.
- Comprehensive immunophenotyping with spectral flow cytometry and multi-domain injury assessment.
Limitations
- Endotoxin-induced murine model may not capture full heterogeneity of human ARDS.
- Translational biomarkers and dosing/therapeutic windows require human validation.
Future Directions: Identify CCR5+ NK signatures in human ARDS, conduct early-phase trials of CCR5 antagonists with biomarker enrichment, and explore synergy with lung-protective and immunomodulatory strategies.
Acute lung injury (ALI) is a life-threatening clinical syndrome characterized by intense inflammation and pulmonary physiologic dysfunction. While innate immune cells dominate early ALI pathology, lymphocytes are increasingly recognized as important contributors. Prior work demonstrated that natural killer (NK) cells are recruited through CCR5 leading to damage following ischemic lung injury. As endotoxin-induced ALI is an important pre-clinical model for acute respiratory distress syndrome (ARDS), here we asked whether NK cells recruited through CCR5 mediated injury in this clinically relevant model. We examined CCR5 and NK cells in a C57BL/6 mouse model of endotoxin-induced ALI using spectral flow cytometry and genetic knockout animals. We found that CCR5 ligands and CCR5 NK cells were increased during ALI relative to no-injury control mice. CCR5-positive NK cells had markers of tissue residence and CCR5 inhibition reduced NK cell trafficking as measured in the bronchoalveolar lavage. Further, CCR5 inhibition ameliorated lung injury across all domains. CCR5 inhibition had less of an impact on T cell trafficking, and these cells had relatively less CCR5 expression. Adoptive transfer of Ccr5-null NK cells preceding ALI resulted in reduced trafficking and injury compared to wildtype transfers. NK cell depletion and CCR5 inhibition were effective even when administered 2 hours after LPS administration. indicating potential relevance for clinical translation. In summary, this study cements CCR5-positive NK cells as mechanistically important in a clinically relevant acute lung injury model. Inhibition of CCR5-positive NK cells may have translational application for some ARDS endotypes.